
SANTA CRUZ BIOTECHNOLOGY, INC.

KIAA1210 (E-19): sc-247291



BACKGROUND

KIAA1210 is a 1,709 amino acid protein that maps to human chromosome X. The X and Y chromosomes are the human sex chromosomes. Chromosome X consists of about 153 million base pairs and nearly 1,000 genes. The combination of an X and Y chromosome lead to normal male development while two copies of X lead to normal female development. There are a number of conditions related to an unusual number and combination of sex chromosomes being inherited, including Turner's syndrome, Klinefelter's syndrome and Triple X syndrome. Color blindness, hemophilia, and Duchenne muscular dystrophy are well known X chromosome-linked conditions which affect males more frequently as males carry a single X chromosome.

REFERENCES

- 1. Gianfrancesco, F., et al. 2001. Differential divergence of three human pseudoautosomal genes and their mouse homologs: implications for sex chromosome evolution. Genome Res. 11: 2095-2100.
- Bernardino-Sgherri, J., et al. 2002. Overall DNA methylation and chromatin structure of normal and abnormal X chromosomes. Cytogenet. Genome Res. 99: 85-91.
- 3. Deeb, S.S. 2005. The molecular basis of variation in human color vision. Clin. Genet. 67: 369-377.
- Bojesen, A., et al. 2006. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care 29: 1591-1598.
- Maggio, M.C., et al. 2007. Polycystic ovary and gonadoblastoma in Turner's syndrome. Minerva Pediatr. 59: 397-401.
- Helderman-van den Enden, A.T., et al. 2009. Recurrence risk due to germ line mosaicism: duchenne and becker muscular dystrophy. Clin. Genet. 75: 465-472.

CHROMOSOMAL LOCATION

Genetic locus: KIAA1210 (human) mapping to Xq24.

SOURCE

KIAA1210 (E-19) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of KIAA1210 of human origin.

PRODUCT

Each vial contains 200 μg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-247291 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, **D0 NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

KIAA1210 (E-19) is recommended for detection of KIAA1210 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for KIAA1210 siRNA (h): sc-90977, KIAA1210 shRNA Plasmid (h): sc-90977-SH and KIAA1210 shRNA (h) Lentiviral Particles: sc-90977-V.

Molecular Weight of KIAA1210: 187 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluo-rescence: use donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.